Cefepime Linked to Higher Death Risk in New Study
A widely used hospital antibiotic has come under renewed scrutiny after a major analysis found a possible association between cefepime higher death risk and treatment with the drug compared with other beta-lactam antibiotics.
The study, published in JAMA Network Open, examined data from 110 randomized clinical trials involving 22,608 patients. Researchers found that 6.6% of patients who received cefepime died, compared with 6.2% of patients who received other beta-lactam antibiotics. The researchers calculated a 94.4% probability that cefepime was associated with higher odds of death.
However, the findings require careful interpretation.
The analysis does not prove that cefepime directly caused the deaths. Many of the patients included in the research were seriously ill, including people with severe bacterial infections and febrile neutropenia. Researchers and accompanying commentators said the mortality signal could potentially involve dosing, inadequate drug exposure or excessive drug exposure rather than the antibiotic molecule alone.
The findings nevertheless reopen a safety question that has existed for years.
What Is Cefepime?
Cefepime is a fourth-generation cephalosporin antibiotic used to treat serious bacterial infections.
Unlike antibiotics intended for relatively mild infections, cefepime is generally used in hospital settings when clinicians need broad antibacterial coverage. It can be used for conditions including pneumonia, urinary tract infections, meningitis, severe bacterial infections and febrile neutropenia.
Febrile neutropenia is particularly important because it can occur when a person has a dangerously low number of infection-fighting white blood cells and develops a fever. It can represent a medical emergency, especially in patients receiving cancer treatment.
Cefepime is also valued because it can provide activity against certain difficult-to-treat bacteria.
That means any discussion about its safety has to be balanced against the consequences of leaving a serious bacterial infection inadequately treated.
New Study Examines Cefepime Higher Death Risk
The new research was designed to revisit longstanding questions about cefepime safety.
Researchers conducted a systematic review and Bayesian meta-analysis of randomized clinical trials comparing cefepime with other beta-lactam antibiotics. The investigators searched several medical databases and clinical-trial registries for eligible studies through May 25, 2026.
The final analysis included 110 randomized trials and 22,608 patients.
Of those patients:
- 11,726 received cefepime
- 10,882 received another beta-lactam antibiotic
- 778 cefepime-treated patients died
- 674 patients in the comparison groups died
That translated into mortality rates of approximately 6.6% and 6.2%, respectively. The pooled odds ratio was 1.10, with a 95% credible interval of 0.98 to 1.24.
Based on the Bayesian analysis, researchers estimated a 94.4% probability that cefepime was associated with higher mortality than the comparison antibiotics.
That number should not be interpreted as meaning that 94.4% of cefepime patients are at risk of dying.
Instead, it represents the statistical probability, within the study’s Bayesian framework, that cefepime was associated with higher mortality than the comparator treatments.
The Signal Was Stronger in Adults
One of the most notable findings involved differences between adults and children.
The researchers reported that the mortality signal was concentrated in adult patients. They did not find a similar clear signal among children.
That distinction is important because the study included patients across different ages and medical conditions.
The analysis also found stronger signals in certain clinical situations. The highest probability of harm was observed among patients being treated for febrile neutropenia, where the estimated probability of increased mortality was 96.1%.
However, these results still represent associations from a pooled analysis. They do not establish that cefepime was the direct cause of individual deaths.
Patients requiring cefepime may already have life-threatening infections or other serious illnesses. Separating the effect of the underlying disease from the potential effect of an antibiotic is one of the major challenges in evaluating mortality outcomes.
Higher Doses Also Raised Questions
The analysis also examined cefepime dosing.
Researchers reported that standard and higher doses, including doses of 2 grams every 12 hours or more, had a greater than 93% probability of an increased mortality signal. Lower doses also showed a statistical signal, although the probability was lower at 80.5%.
This finding has fueled discussion about whether the issue may be partly related to how cefepime is administered rather than simply whether the drug is used.
Cefepime dosing can be complicated because the medication is eliminated through the kidneys.
When kidney function is reduced, the body may not clear cefepime as efficiently. If dosing is not adjusted appropriately, concentrations can become too high.
That can increase the risk of neurological complications.
Why Kidney Function Matters With Cefepime
Cefepime has previously been associated with neurological side effects, particularly in patients with impaired kidney function.
Severe adverse effects can include confusion, decreased consciousness and seizures. The risk can become more important when the dose is not appropriately adjusted for a patient’s kidney function.
At the same time, giving too little antibiotic can create another problem.
If drug exposure is inadequate, the antibiotic may fail to control the infection effectively. This creates a difficult balance between treating the infection aggressively enough and avoiding excessive exposure.
That is one reason researchers have raised the possibility that the mortality signal could be related to both underexposure and overexposure.
An accompanying commentary argued that the question may ultimately be more about finding the appropriate dose for individual patients than simply determining whether cefepime should be used at all.
Earlier Research Also Raised Safety Concerns
The new study is not the first investigation to raise questions about cefepime mortality.
Cefepime has been used medically since its approval in the 1990s. In 2007, an earlier meta-analysis reported a 26% higher relative risk of death among patients receiving cefepime compared with other beta-lactam antibiotics.
That earlier finding prompted additional examination.
The U.S. Food and Drug Administration later reviewed available evidence and did not find a statistically significant increase in mortality. Some of the data involved unpublished, industry-sponsored trials, which has contributed to continuing debate about the evidence base.
The latest analysis attempted to expand the evidence by incorporating additional randomized trials, including unpublished studies made available through the FDA.
That makes the new research important, but it also means the findings need to be considered alongside the earlier evidence rather than in isolation.
Published Trials Produced a Stronger Signal
Researchers performed another analysis using only published, peer-reviewed trials.
That subgroup included 73 studies and 15,411 patients.
Within this group, the estimated probability that cefepime was associated with higher mortality increased to 98.6%. The estimated odds ratio was 1.17, with a 95% credible interval of 1.02 to 1.34.
The researchers estimated a number needed to harm ranging from approximately 111 to 227, depending on the analysis.
In simple terms, the number needed to harm is an estimate of how many patients would need to receive a treatment for one additional adverse outcome to occur compared with the alternative treatment.
It is important not to interpret this as a prediction for an individual patient.
The actual risk can vary substantially depending on the patient’s infection, age, kidney function, other medical conditions, dose and alternative treatments available.
Why the Study Does Not Mean Cefepime Should Be Abandoned
Despite the findings, the researchers did not call for cefepime to be removed from medical practice.
That distinction is critical.
Cefepime remains an important antibiotic for treating serious infections, including infections involving bacteria that may be resistant to other treatments. In some situations, physicians need an antibiotic with broad activity quickly because delaying effective treatment can itself carry serious risks.
The researchers instead called for a more nuanced discussion of cefepime safety.
Future research could examine whether individualized dosing, closer monitoring of kidney function and other strategies can reduce potential risks while maintaining effective treatment.
The authors also highlighted the importance of additional research capable of determining exactly why the mortality signal appeared.
What Patients Should Know About the Findings
For patients, the study should not be interpreted as a reason to stop or refuse an antibiotic without discussing the situation with a healthcare professional.
Cefepime is typically administered by healthcare providers in clinical settings. The choice of antibiotic depends on factors such as the suspected infection, laboratory results, bacterial susceptibility, kidney function, allergies, other medications and the patient’s overall condition.
A medication associated with a statistical safety signal in a population study does not automatically mean that it is unsafe for every person.
In fact, for someone with a serious bacterial infection, receiving an effective antibiotic can be an essential part of treatment.
The new findings are therefore more relevant to how clinicians evaluate antibiotic selection, dosing and monitoring than to self-directed decisions about medication.
A Larger Antibiotic Safety Issue
The cefepime debate also highlights a broader challenge in modern medicine: antibiotics must be powerful enough to treat dangerous infections while being used as safely and precisely as possible.
Antibiotic resistance is already a major global health concern.
The World Health Organization reported in 2026 that one in six laboratory-confirmed bacterial infections causing common infections worldwide in 2023 was resistant to antibiotic treatment. The organization also reported that resistance increased in more than 40% of the pathogen-antibiotic combinations it monitored between 2018 and 2023.
That makes effective antibiotics extremely valuable.
Doctors must therefore balance several competing considerations. Using an antibiotic that is too narrow may fail to cover the bacteria causing a serious infection. Using an overly broad drug unnecessarily can contribute to resistance and other complications.
Cefepime sits within that complex medical landscape.
Researchers Call for More Evidence
The latest study adds substantial data to a safety debate that has continued for nearly two decades.
The analysis involved more than 22,000 patients across 110 randomized trials, making it considerably larger than many earlier evaluations. Yet important uncertainties remain.
For example, all-cause mortality is a broad outcome. A patient may die because of severe infection, cancer, organ failure or another underlying condition rather than because of the antibiotic being studied.
Researchers also noted limitations involving the design and reporting of some trials. Many studies were open-label, and the investigators had limited information about certain unpublished trials.
An accompanying commentary argued that additional access to individual patient-level data could provide a more detailed assessment than repeatedly analyzing summary statistics from older trials.
That could help researchers determine whether particular patients are more vulnerable to potential cefepime-related risks and whether specific dosing strategies make a meaningful difference.
What Comes Next for Cefepime?
The new findings are likely to encourage additional research into cefepime dosing, kidney function and patient-specific treatment strategies.
Researchers will need to determine whether the observed mortality association reflects a direct drug effect, inappropriate exposure in some patients, differences in disease severity or a combination of factors.
For now, the evidence presents a more complicated picture than the headline alone suggests.
The study identified a measurable statistical signal, particularly among adults, patients with febrile neutropenia and some higher-dose treatment groups. But it did not establish that cefepime directly causes death, nor did its authors recommend abandoning the antibiotic.
Instead, the findings support continued scrutiny of how cefepime is prescribed and monitored.
For hospitals and clinicians, that could mean renewed attention to appropriate dosing, kidney function and patient-specific risk factors.
For patients, the main takeaway is that antibiotic decisions should remain individualized and guided by medical professionals who can weigh the risks of the drug against the risks of the infection.
As researchers continue to investigate the cefepime higher death risk signal, the central question is no longer simply whether the antibiotic should be used. It is increasingly about determining which patients benefit from cefepime, how it should be dosed and how potential safety risks can be minimized while preserving its ability to treat serious bacterial infections.
